Loading…
Employees: 99
Size CapsoVision (CV) is a United States Health Care company (Medical Specialties) with a market value of $336M, the 3015th largest of 3,117 United States companies the cockpit tracks. Shares closed at $6.32 on 6 Nov 2026.
Performance Over six months the shares fell 11.2%, against -6.8% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 20 in its peer set.
Growth Revenue grew 15.3% over the last twelve months (peer median +5.3%); the operating margin is -217.1% (peer median 4.9%).
Valuation It trades at 23.6× enterprise value to sales against a peer median of 3.9× (2nd most expensive of 21).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | $13.9M | $13.6M | $11.8M | $9.75M |
| Revenue growth | — | +15% | +21% | — |
| Gross profit | $7.07M | $7.17M | $6.38M | $5.49M |
| EBITDA | -$29.6M | -$24.8M | -$19.5M | -$10.8M |
| Net income | -$29.8M | -$25.3M | -$19.9M | -$11.3M |
| Free cash flow | -$27.9M | -$23.0M | -$20.2M | -$11.6M |
| Capital expenditure | $68,000 | $90,000 | $153,000 | $754,180 |
| Total debt | $687,000 | $887,000 | $1.24M | $1.51M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CV | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.5% | -5.1% | 11th highest of 21 |
| 6-month return | -11.2% | -6.8% | 9th lowest of 20 |
| Distance from 52-week high | -58.9% | -27.1% | 2nd lowest of 21 |
| Revenue growth (TTM) | +15.3% | +5.3% | 7th highest of 21 |
| Operating margin | -217.1% | 4.9% | lowest of 21 |
| EV / Sales | 23.6× | 3.9× | 2nd most expensive of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | 23.6× | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | 4.7× | 22.5% | -10.9% |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 2.9× | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 1.6× | n/a | n/a |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | 9.8× | n/a | n/a |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | 6.2× | 31.9% | -4.5% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 0.8× | -19.8% | -28.5% |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | 200.7× | n/a | n/a |
| Tauns Laboratories 197A.T | Japan | $322M | -2% | -23% | 29% | 4.8× | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 1.6× | -19.9% | -0.1% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | 8.1× | n/a | n/a |
| Kontour (Xi'an) Medical Technology 688314.SS | China | $321M | -39% | +4% | 27% | 5.3× | 6.1% | +16.4% |
| Surgical Science Sweden SUS.ST | Sweden | $321M | +86% | +8% | 16% | 2.4× | 4.3% | +56.8% |
| Japan Eyewear 5889.T | Japan | $321M | -7% | +15% | 32% | 3.1× | -9.0% | +20.2% |
| Orthofix Medical OFIX | United States | $321M | -32% | +3% | -4% | 0.6× | n/a | n/a |
| Improve Medical Instruments 300030.SZ | China | $320M | -17% | -2% | 4% | 4.2× | 26.0% | -11.9% |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 6.5× | n/a | n/a |
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 1.4× | 0.1% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | 1.1× | -12.7% | -1.3% |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | 3.7× | -13.2% | +36.8% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | 6.4× | n/a | n/a |